Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sodium phosphate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    178 result(s) found for: Sodium phosphate. Displaying page 9 of 9.
    « Previous 1  2  3  4  5  6  7  8  9 
    EudraCT Number: 2007-007456-34 Sponsor Protocol Number: 3100N0-2213-WW Start Date*: 2009-09-04
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: Estudio de fase 2, multicéntrico, aleatorizado, controlado con producto activo, de grupos paralelos, búsqueda de dosis y de la seguridad de la proteína morfogenética de hueso humano recombinante 2 ...
    Medical condition: Sujetos con disminución de la densidad mineral ósea (DMO) en riesgo de fractura de cadera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10031282 Osteoporosis PT
    Population Age: Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) PL (Completed) FI (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001833-87 Sponsor Protocol Number: 00600 Start Date*: 2008-06-20
    Sponsor Name:University Medical Center Freiburg
    Full Title: Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malig...
    Medical condition: malign lymphoma (primary high risks patients: - therapy refractory / relapsed NHL - therapy refractory / relapsed M. Hodgkin - Burkitt-NHL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006595 Burkitt's lymphoma LLT
    9.1 10029609 Non-Hodgkin's lymphoma unspecified histology aggressive recurrent LLT
    9.1 10029610 Non-Hodgkin's lymphoma unspecified histology aggressive refractory LLT
    9.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005180-40 Sponsor Protocol Number: Protocol_PPB_TKA_31122017 Start Date*: 2018-02-19
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of the popliteal plexus block on postoperative pain after total knee arthroplasty - a randomized, controlled, double-blinded study
    Medical condition: Postoperative posterior pain after total knee arthroplasty
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023469 Knee arthroplasty PT
    20.0 10042613 - Surgical and medical procedures 10002325 Anesthesia local LLT
    20.0 10042613 - Surgical and medical procedures 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001024-34 Sponsor Protocol Number: OraPAT-IE-GAMES Start Date*: 2021-12-15
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis.
    Medical condition: infective endocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10014666 Endocarditis bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000705-20 Sponsor Protocol Number: EsPhALL2017/COGAALL1631 Start Date*: 2017-12-11
    Sponsor Name:Università degli Studi Milano Bicocca
    Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
    Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005593-38 Sponsor Protocol Number: NN9924-4257 Start Date*: 2016-09-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. A 52 week Randomised, Open-label,...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004187-56 Sponsor Protocol Number: HIT-HGG-2013 Start Date*: 2017-04-24
    Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen
    Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ...
    Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years.
    Disease: Version SOC Term Classification Code Term Level
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066254 Gliomatosis cerebri PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017701 Ganglioglioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018340 Gliosarcoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000111-69 Sponsor Protocol Number: PAC303 Start Date*: 2020-08-04
    Sponsor Name:CTI BioPharma Corp.
    Full Title: PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thro...
    Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001020-20 Sponsor Protocol Number: NKV101983 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title:
    Medical condition: Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) SK (Completed) HU (Completed) AT (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005397-34 Sponsor Protocol Number: Issue1 Start Date*: 2012-02-24
    Sponsor Name:University Hospital Bristol NHS Foundation Trust
    Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study)
    Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10050081 Neonatal hypoxia PT
    14.1 10036585 - Pregnancy, puerperium and perinatal conditions 10028946 Neonatal hypoxia and asphyxia HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:Stichting European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing) BE (Completed) DE (Completed) CZ (Completed) DK (Completed) FR (Completed) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005825-12 Sponsor Protocol Number: PB-06-002 Start Date*: 2009-06-04
    Sponsor Name:Protalix Biotherapeutics
    Full Title: Ensayo clinico de fase 3, multicéntrico, en abierto y con cambio de tratamiento para evaluar la seguridad y eficacia de Glucocerebrosidasa Humana Recombinante expresada en células vegetales (prGCD)...
    Medical condition: Enfermedad de Gaucher Gaucher Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018048 Gaucher's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000531-27 Sponsor Protocol Number: NL43510 Start Date*: 2014-02-11
    Sponsor Name:University Medical Center Utrecht
    Full Title: Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial
    Medical condition: Encephalopathy with electrical status epilepticus in sleep, also called ESES syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10032061 Other forms of epilepsy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FI (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) DK (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000133-40 Sponsor Protocol Number: 2016-2369 Start Date*: 2016-05-25
    Sponsor Name:Gustave Roussy
    Full Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
    Medical condition: Relapsed or refractory tumors in children
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012417-22 Sponsor Protocol Number: CTKI258A2204 Start Date*: 2010-04-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation
    Medical condition: Patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005405-37 Sponsor Protocol Number: NH19960 Start Date*: 2006-06-28
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
    Medical condition: Anemic patients undergoing chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) CZ (Completed) EE (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001772-28 Sponsor Protocol Number: PAC203 Start Date*: 2017-10-23
    Sponsor Name:CTI BioPharma Corp.
    Full Title: Phase 3 Study (PACIFICA): A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essent...
    Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL), Post polycythaemia vera myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) SE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022445-20 Sponsor Protocol Number: CA204006 Start Date*: 2011-11-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.
    Medical condition: Untreated Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) BE (Completed) AT (Completed) GR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 22:03:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA